Bleeding profile and endometrial safety of continuous combined regimens 1 mg 17β-estradiol/trimegestone versus 1 or 2 mg 17β-estradiol/ norethisterone acetate in postmenopausal women

Gynecological Endocrinology

Volumn 21, Issue 3, 2005, Pages 142-148

  Bouchard, P ^a   De Cicco Nardone, F ^b   Spielmann, D ^c   Garcea, N ^d  

^a HÔPITAL SAINT ANTOINE   (France)

^b CATHOLIC UNIVERSITY   (Italy)

^c Searle European Clinical R and D   (France)

^d SAN GIOVANNI ADDOLORATA HOSPITAL   (Italy)

Author keywords

Amenorrhea; Bleeding profile; Continuous combined hormone replacement therapy; Endometrial safety; Estradiol; Menopause; Norethisterone acetate; Trimegestone

Indexed keywords

ESTRADIOL; ESTRADIOL PLUS NORETHISTERONE ACETATE; ESTRADIOL PLUS TRIMEGESTONE; TRIMEGESTONE; UNCLASSIFIED DRUG;

ADULT; AMENORRHEA; ARTICLE; BREAST CARCINOMA; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; ENDOMETRIUM; ENDOMETRIUM HYPERPLASIA; ESTROGEN THERAPY; EUROPE; FEMALE; HEADACHE; HUMAN; HUMAN TISSUE; ISRAEL; MAJOR CLINICAL STUDY; MASTALGIA; MENOPAUSAL SYNDROME; METRORRHAGIA; MULTICENTER STUDY; POSTMENOPAUSE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME; UTERUS; UTERUS BIOPSY; UTERUS BLEEDING;

COMPARATIVE STUDY; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; ENDOMETRIUM; ESTRADIOL; ESTROGEN REPLACEMENT THERAPY; EUROPE; FEMALE; HUMANS; ISRAEL; MENSTRUAL CYCLE; MIDDLE AGED; NORETHINDRONE; POSTMENOPAUSE; PROMEGESTONE; TREATMENT OUTCOME; UTERINE HEMORRHAGE;

EID: 27744499881     PISSN: 09513590     EISSN: 14730766     Source Type: Journal    
DOI: 10.1080/09513590500168464     Document Type: Article

References (30)

1. Campbell S, Whitehead M. Oestrogen therapy and the menopausal syndrome. Clin Obstet Gynaecol 1977;4:31-47.
2. Whitehead MI. The effects of oestrogens and progestogens on the postmenopausal endometrium. Maturitas 1978;1:87-98.
3. Voigt LF, Weiss NS, Chu J, Daling JR, McKnight B, van Belle G. Progestagen supplementation of exogenous oestrogens and risk of endometrial cancer. Lancet 1991;338:274-277.
4. Cullberg G, Knutsson F, Mattsson L-Å. A new combination of conjugated equine oestrogens and medroxyprogesterone for treatment of climacteric complaints. Maturitas 1984;6:55-63.
5. Gelfand MM, Ferenczy A. A prospective 1-year study of estrogen and progestin in postmenopausal women: effects on the endometrium. Obstet Gynecol 1989;74:398-402.
6. Woodruff JD, Pickar JH. Incidence of endometrial hyperplasia in postmenopausal women taking conjugated estrogens (Premarin) with medroxyprogesterone acetate or conjugated estrogens alone. Am J Obstet Gynecol 1994;170:1213-1223.
7. Persson I, Adami H-O, Bergkvist L, Lindgren A, Pettersson B, Hoover R, Schairer C. Risk of endometrial cancer after treatment with oestrogens alone or in conjunction with progestogens: results of a prospective study. BMJ 1989;298:147-151.
8. Philibert D, Bouchoux F, Degryse M, Lecaque D, Petit F, Gaillard M. The pharmacological profile of a novel norpregnane progestin (trimegestone). Gynecol Endocrinol 1999;13:316-326.
9. Winneker RC, Bitran D, Zhang Z. The preclinical biology of a new potent and selective progestin: trimegestone. Steroids 2003;68:915-920.
10. Sherwin BB. Progestogens used in menopause. Side effects, mood and quality of life. J Reprod Med 1999;44:227-232.
11. Sherwin BB. The impact of different doses of estrogen and progestin on mood and sexual behavior in postmenopausal women. J Clin Endocrinol Metab 1991;72:336-343.
12. Al-Azzawi F, Wahab M, Thompson J, Whitehead M, Thompson W. Acceptability and patterns of uterine bleeding in sequential trimegestone-based hormone replacement therapy: a dose-ranging study. Hum Reprod 1999;14:636-641.
13. Al-Azzawi F, Wahab M, Thompson J, Pornel B, Hirvonen E, Ylikorkala O, van der Mooren MJ, Dillon J, Magaril C. Acceptability and patterns of endometrial bleeding in estradiol-based HRT regimens: a comparative study of cyclical sequential combinations of trimegestone or norethisterone acetate. Climacteric 2001;4:343-354.
14. Bouali Y, Gaillard-Kelly M, Marie PJ. Effect of trimegestone alone or in combination with estradiol on bone mass and bone turnover in an adult rat model of osteopenia. Gynecol Endocrinol 2001;15:48-55.
15. Lepescheux L, Secchi J, Gaillard-Kelly M, Miller P. Effects of 17β-estradiol and trimegestone alone, and in combination, on the bone and uterus of ovariectomized rats. Gynecol Endocrinol 2001;15:312-320.
16. Meuwissen JH, Beijers-De Bie L, Vihtamaki T, Tuimala R, Siseles N, Magaril C, The HS, Houben PW, Murga M, Spielmann D, et al. A 1-year comparison of the efficacy and clinical tolerance in postmenopausal women of two hormone replacement therapies containing estradiol in combination with either norgestrel or trimegestone. Gynecol Endocrinol 2001;15:349-358.
17. Ross D, Godfree V, Cooper A, Pryse-Davies J, Whitehead MI. Endometrial effects of three doses of trimegestone, a new orally active progestogen, on the postmenopausal endometrium. Maturitas 1997;28:83-88.
18. Sultan E, Perret C, Verdier P, et al. Pharmacokinetics of estradiol and trimegestone in postmenopausal women after multiple administration of 2 mg estradiol once a day for 14 days followed by 2 mg estradiol/0.5 mg trimegestone once a day for 14 days. Climacteric 1999;2:221.
19. Warming L, Ravn P, Spielmann D, Delmas P, Christiansen C. Trimegestone in a low-dose, continuous-combined hormone therapy regimen prevents bone loss in osteopenic postmenopausal women. Menopause 2004;11:337-342.
20. Marslew U, Riis BJ, Christiansen C. Bleeding patterns during continuous combined estrogen-progestogen therapy. Am J Obstet Gynecol 1991;164:1163-1168.
21. Odmark I-S, Jonsson B, Backstrom T. Bleeding patterns in postmenopausal women using continuous combination hormone replacement therapy with conjugated estrogen and medroxyprogesterone acetate or with 17β-estradiol and norethindrone acetate. Am J Obstet Gynecol 2001;184:1131-1138.
22. Gambacciani M, Spielmann D, Genazzani AR; Trimegestone 301 Study Group. Efficacy on climacteric symptoms of a continuous combined regimen of 1 mg 17β-estradiol and trimegestone versus two regimens containing 1 or 2 mg 17β-estradiol and noresthisterone acetate. Gynecol Endocrinol 2005;21(2):65-73.
23. Granberg S, Wikland M, Karlsson B, Norstrom A, Friberg L-G. Endometrial thickness as measured by endovaginal ultrasonography for identifying endometrial abnormality. Am J Obstet Gynecol 1991;164:47-52.
24. Nasri MN, Coast GJ. Correlation of ultrasound findings and endometrial histopathology in postmenopausal women. Br J Obstet Gynaecol 1989;96:1333-1338.
25. Bjarnason NH, Christiansen C. The influence of thinness and smoking on bone loss and response to hormone replacement therapy in early postmenopausal women. J Clin Endocrinol Metab 2000;85:590-596.
26. Geisler J, Omsjo IH, Helle SI, Ekse D, Silsand T, Lonning PE. Plasma oestrogen fractions in postmenopausal women receiving hormone replacement therapy: influence of route of administration and cigarette smoking. J Endocrinol 1999;162:265-270.
27. Committee for Proprietary Medicinal Products. Points to consider on hormone replacement therapy. London: European Agency for the Evaluation of Medicinal Products; 1997.
28. Writing Group for the PEPI Trial. Effects of hormone replacement therapy on endometrial histology in postmenopausal women. The Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial. JAMA 1996;275:370-375.
29. Pickar JH, Yeh I-T, Wheeler JE, Cunnane MF, Speroff L. Endometrial effects of lower doses of conjugated equine estrogens and medroxyprogesterone acetate: two year sub-study results. Fertil Steril 2003;80:1234-1240.
30. Sardo AD, Radhakrishnan S. Endometrial carcinoma on continuous combined HRT: case report and literature review. Maturitas 2004;48:171-175.